文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

托珠单抗治疗COVID-19的预后与预测生物标志物:COVACTA随机对照试验探索性分析

Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.
PubMed 文献 · Crit Care Med · 2022-01-01
一句话结论重症COVID-19肺炎中,铁蛋白可预测托珠单抗疗效:铁蛋白高者托珠单抗较安慰剂28天临床结局更优。

COVACTA试验的探索性分析纳入北美和欧洲住院的重症COVID-19肺炎成人患者,随机2:1接受静脉托珠单抗8 mg/kg或安慰剂。在安慰剂组中,除乳酸脱氢酶和D-二聚体外,所有候选生物标志物均对28天死亡率、机械通气、临床状态和出院时间有强预后价值。在托珠单抗组中,铁蛋白对28天死亡率(交互p=0.03)、机械通气(交互p=0.01)和临床状态(交互p=0.02)显示出预测价值;高铁蛋白水平与托珠单抗相比安慰剂更好的临床结局相关。

要点

  • 在重症COVID-19肺炎患者中,铁蛋白可预测托珠单抗疗效:高铁蛋白者托珠单抗较安慰剂28天死亡率、机械通气、临床状态更优(交互p分别为0.03、0.01、0.02)。
  • 安慰剂组中,除乳酸脱氢酶和D-二聚体外,所有候选生物标志物(IL-6、CRP、铁蛋白、淋巴细胞、单核细胞、中性粒细胞、血小板)均对28天临床结局有强预后价值。
  • 该分析为COVACTA试验的探索性分析,托珠单抗组295例、安慰剂组142例,结果需前瞻性验证,不能直接作为床旁决策阈值。
  • 托珠单抗用法为静脉8 mg/kg(原文方案),但本研究为探索性分析,不提供通用推荐剂量。

适用人群与场景

  • 北美和欧洲医院住院的成人重症COVID-19肺炎患者,接受标准治疗。
  • 随机2:1接受静脉托珠单抗8 mg/kg或安慰剂。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:多中心、随机、双盲、安慰剂对照、3期试验的探索性分析;样本量:托珠单抗组295例,安慰剂组142例;中心数:原文未提及。
  • 干预与对照:静脉托珠单抗8 mg/kg vs 安慰剂,随机2:1。
  • 主要终点:28天临床状态(7分类序贯量表)、死亡率、出院时间、机械通气(若随机时未通气)。
  • 安慰剂组中,除乳酸脱氢酶和D-二聚体外,所有候选生物标志物均对28天死亡率、机械通气、临床状态和出院时间有强预后价值。
  • 托珠单抗组中,铁蛋白对28天死亡率(交互p=0.03)、机械通气(交互p=0.01)、临床状态(交互p=0.02)有预测价值;高铁蛋白水平与托珠单抗相比安慰剂更好的临床结局相关。

证据类型、等级与局限

  • 证据类型:多中心、随机、双盲、安慰剂对照、3期试验的探索性分析。
  • 证据等级或推荐强度:原文未提及。
  • 局限:探索性分析;样本量有限(托珠单抗组295例,安慰剂组142例);中心数未提及;结果需前瞻性验证。

对床旁实践的改变

  • 在重症COVID-19肺炎患者中,铁蛋白可能有助于识别可能从托珠单抗获益的人群,但该发现为探索性,不能作为常规床旁决策阈值。
  • 其他生物标志物(除乳酸脱氢酶和D-二聚体外)有预后价值,可用于风险分层,但需结合临床。
  • 不改变现有托珠单抗使用推荐,因证据来自探索性分析,需进一步验证。

指南或共识出处

  • COVACTA trial(原文未提供完整指南或共识名称)

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVES: To explore candidate prognostic and predictive biomarkers identified in retrospective observational studies (interleukin-6, C-reactive protein, lactate dehydrogenase, ferritin, lymphocytes, monocytes, neutrophils, d-dimer, and platelets) in patients with coronavirus disease 2019 pneumonia after treatment with tocilizumab, an anti-interleukin-6 receptor antibody, using data from the COVACTA trial in patients hospitalized with severe coronavirus disease 2019 pneumonia.

DESIGN: Exploratory analysis from a multicenter, randomized, double-blind, placebo-controlled, phase 3 trial.

SETTING: Hospitals in North America and Europe.

PATIENTS: Adults hospitalized with severe coronavirus disease 2019 pneumonia receiving standard care.

INTERVENTION: Randomly assigned 2:1 to IV tocilizumab 8 mg/kg or placebo.

MEASUREMENTS AND MAIN RESULTS: Candidate biomarkers were measured in 295 patients in the tocilizumab arm and 142 patients in the placebo arm. Efficacy outcomes assessed were clinical status on a seven-category ordinal scale (1, discharge; 7, death), mortality, time to hospital discharge, and mechanical ventilation (if not receiving it at randomization) through day 28. Prognostic and predictive biomarkers were evaluated continuously with proportional odds, binomial or Fine-Gray models, and additional sensitivity analyses. Modeling in the placebo arm showed all candidate biomarkers except lactate dehydrogenase and d-dimer were strongly prognostic for day 28 clinical outcomes of mortality, mechanical ventilation, clinical status, and time to hospital discharge. Modeling in the tocilizumab arm showed a predictive value of ferritin for day 28 clinical outcomes of mortality (predictive interaction, p = 0.03), mechanical ventilation (predictive interaction, p = 0.01), and clinical status (predictive interaction, p = 0.02) compared with placebo.

CONCLUSIONS: Multiple biomarkers prognostic for clinical outcomes were confirmed in COVACTA. Ferritin was identified as a predictive biomarker for the effects of tocilizumab in the COVACTA patient population; high ferritin levels were associated with better clinical outcomes for tocilizumab compared with placebo at day 28.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Tom J, Bao M, Tsai L, et al. Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial. Crit Care Med. 2022. PMID: 34612846. doi:10.1097/CCM.0000000000005229

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。